One of these nine patients had cholangiocarcinoma that harbored ERBB2 missense mutation (V777L) (Fig 2B), which was the therapeutic target for patients with different types of tumors as reported [19,20]. This evidence concerns the gene ERBB2 and cholangiocarcinoma.